A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naive patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial - Mease, P J; Smolen, J S; Behrens, F (Ann Rheum Dis, 2020)